Parkinson's Disease in 68 Market Projected to Reach USD 13.2 Billion by 2034

Parkinson's disease (PD) is the second most common neurodegenerative disorder globally, characterized by the progressive loss of dopamine-producing neurons in the brain. The condition leads to motor symptoms such as tremors, rigidity, and bradykinesia, as well as non-motor complications like depression, cognitive impairment, and sleep disturbances.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73647

With over 10 million people worldwide affected and prevalence rising with an aging population, Parkinson's disease represents one of the most urgent challenges in neurology. While current therapies are primarily symptomatic, rapid advances in gene therapy, cell-based interventions, digital monitoring, and disease-modifying treatments (DMTs) are redefining the landscape. The Parkinson's Disease Market is thus poised for strong growth through 2034 as innovation meets unmet clinical need.

Market Overview
• Market Size (2024): USD 5.4 billion (estimated)
• Forecast (2034): USD 13.2 billion
• CAGR (2024-2034): ~9.4%

Key Growth Drivers:
• Rising global prevalence of Parkinson's disease, especially among aging populations.
• Ongoing innovation in dopaminergic therapies, DMTs, and precision drug delivery.
• Increasing investment in AI-driven diagnostics and wearable monitoring technologies.
• Growing support from foundations and government bodies for neurological research.

Challenges:
• Absence of curative treatments.
• Adverse effects and fluctuating efficacy of long-term dopaminergic therapy.
• Complexity of clinical trials in neurodegenerative diseases.

Leading Companies:
AbbVie Inc., Novartis AG, Merck & Co. Inc., Biogen Inc., UCB Pharma, GlaxoSmithKline plc, Roche Holding AG, Teva Pharmaceutical Industries, Takeda Pharmaceutical Company, Amneal Pharmaceuticals.

Segmentation Analysis
By Drug Class
• Dopamine Precursors (Levodopa, Carbidopa)
• Dopamine Agonists (Pramipexole, Ropinirole, Rotigotine)
• MAO-B Inhibitors (Rasagiline, Selegiline)
• COMT Inhibitors (Entacapone, Opicapone)
• Amantadine & Anticholinergics
• Disease-Modifying Therapies (Gene & Cell-Based Therapies, Neuroprotective Agents)

By Route of Administration
• Oral
• Injectable
• Transdermal
• Intranasal

By End User
• Hospitals & Neurology Clinics
• Specialty Pharmacies
• Research & Academic Centers

Summary:
Dopamine replacement therapies (Levodopa-based) remain the cornerstone of PD treatment, but MAO-B and COMT inhibitors are increasingly used for adjunct therapy. The fastest-growing segment is disease-modifying and gene-based therapies, reflecting a shift from symptomatic relief to neuroprotection. Transdermal patches and extended-release formulations are also improving patient compliance and minimizing motor fluctuations.

Explore Full Report here: https://exactitudeconsultancy.com/reports/73647/parkinson-s-disease-in-68-market

Regional Analysis
North America
• Largest market share in 2024, driven by a high patient base, favorable reimbursement structures, and cutting-edge R&D pipelines.
• The U.S. leads with approvals of advanced therapies such as AbbVie's Duopa and ongoing trials for gene therapy (Voyager, Neurocrine).
Europe
• Strong research presence in Germany, France, and the UK, supported by European Brain Council and Horizon-funded programs.
• Adoption of advanced therapies for early and late-stage PD management.
Asia-Pacific
• Fastest-growing region (CAGR ~10.5%), with increasing diagnosis rates in Japan, China, and South Korea.
• Rising investment in neurology infrastructure and collaborations with global pharma for clinical trials.
Middle East & Africa
• Steady adoption of generic dopaminergic therapies; expanding specialized neurology care in GCC nations.
• Limited diagnosis and access to advanced treatments in rural regions.
Latin America
• Moderate growth in Brazil and Mexico with government initiatives for neurodegenerative disease awareness.
Summary:
While North America and Europe dominate current market revenues, Asia-Pacific is emerging as a key growth engine, driven by aging demographics, technological adoption, and increasing awareness of early diagnosis.

Market Dynamics
Key Growth Drivers
• Technological integration through AI-driven diagnostics, wearable monitoring devices, and mobile symptom tracking apps.
• Progress in gene therapy targeting GBA1, LRRK2, and alpha-synuclein mutations.
• Advances in stem cell transplantation and deep brain stimulation (DBS) technology.
• Expansion of public-private partnerships in neurodegenerative research.

Key Challenges
• High cost of advanced therapies and surgical interventions.
• Complex etiology of PD complicating biomarker discovery.
• Long regulatory timelines for CNS and gene-based drugs.

Latest Trends
• Development of oral and intranasal formulations of Levodopa for rapid onset.
• Expansion of digital therapeutics and remote patient monitoring systems.
• Integration of AI algorithms in neuroimaging for early disease detection.
• Increasing focus on personalized dosing regimens based on pharmacogenomic insights.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73647

Competitor Analysis
Major Players:
• AbbVie Inc.
• Novartis AG
• Merck & Co. Inc.
• Biogen Inc.
• UCB Pharma
• GlaxoSmithKline plc
• Roche Holding AG
• Teva Pharmaceutical Industries
• Takeda Pharmaceutical Company
• Amneal Pharmaceuticals

Competitive Landscape:
The Parkinson's disease market is highly competitive and innovation-centric, dominated by AbbVie's Duopa, UCB's Neupro, and Roche's gene therapy collaborations. Emerging biotechs such as Voyager Therapeutics, BlueRock (Bayer), and Denali Therapeutics are pioneering gene-editing and cell-replacement approaches. Digital health companies are also collaborating with pharma firms to enhance remote patient monitoring and personalized treatment delivery.

Conclusion
The Parkinson's Disease Market (In-68) is projected to grow from USD 5.4 billion in 2024 to USD 13.2 billion by 2034, at a CAGR of 9.4%. This growth will be driven by advancements in gene therapy, neuroprotective agents, and digital health technologies, marking a transformative decade for neurodegenerative care.

Although challenges such as cost barriers, limited disease-modifying options, and clinical complexity persist, increasing collaboration between pharma, tech innovators, and research institutes is reshaping the industry. Asia-Pacific's strong expansion and integration of AI-based monitoring are further enhancing global market potential.

Key Takeaway: Companies that focus on gene and cell-based therapy, AI-driven diagnostic tools, and digital patient monitoring solutions will lead the next evolution of Parkinson's disease management, bridging innovation with real-world patient care.

This report is also available in the following languages : Japanese (パーキンソン病患者68人), Korean (68년 파킨슨병), Chinese (68 例帕金森病), French (La maladie de Parkinson chez les 68 ans), German (Parkinson-Krankheit in 68), and Italian (Malattia di Parkinson nel 68), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/73647/parkinson-s-disease-in-68-market#request-a-sample

Our More Reports:

PFA Resins for Wire and Cable Market
https://exactitudeconsultancy.com/reports/75210/pfa-resins-for-wire-and-cable-market

Vibration Damping Levelling Feet Market
https://exactitudeconsultancy.com/reports/75211/vibration-damping-levelling-feet-market

High Purity PFA Resins Market
https://exactitudeconsultancy.com/reports/75212/high-purity-pfa-resins-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.